Miami-based Global Stem Calls Group has opened a state-of-the-art GMP facility in the Santiago Mariott. The facility will begin receiving international patients in January, 2016

MIAMI (PRWEB) NOVEMBER 30, 2015

Global Stem Cells Group today announced the opening of a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with the most advanced technologies available, and is operated by a world-class team of qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly manipulated cells.

GMPs are critical for cell therapy success. Understanding and incorporating GMP standards in clinical and pre-clinical research settings establishes a solid foundation on which to build clinical trials and to ensure the safety of biologic products. Good manufacturing practices ensure the safety and efficiency of stem cell products and the patients who receive them. The fundamentals of GMCs are also becoming an important part of the training received by academic researchers in the biotechnology industry, who are at the forefront of developing products for eventual clinical use.

The Global Stem Cells Group GMP 1000 facility will begin receiving international patients in early January 2016.

The GSCG therapeutic center in Santiago—a separate facility from the CMP 1000—will begin seeing international patients as of Dec. 1, 2015 to make its stem cell therapies and facilities available to international patients as well.

For more information, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

###

Global Stem Cells Group Chile CEO Enrique Testart will represent the biotech company at the in First CIMECA Convention in Panama City Feb. 17-19, 2016

MIAMI, Nov.  30, 2015—Global Stem Cells Group Chile CEO Eugene Testart, M.D., will join physicians, aesthetic practitioners

and aesthetics professionals from Central America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, Cosmetology and Anti-Aging (CIMECA), to be held in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new trends in anti-aging stem cell treatments, regenerative medicine and applications in aesthetic medicine.

Global Stem Cells Group subsidiary http://www.stemcelltraining.net will also implement a post-convention training certification course in stem cell techniques and technologies for physicians. The intensive, hands-on course in stem cell harvesting, isolation and re-integration, administered by by accredited and experienced specialists, and participants will receive det

Enrique Testart, M.D.

ailed written protocols and a high-definition video of the procedure. Following course completion, each physician will receive certified stem cell specialist certification with with international validation for in-office stem cell procedures.

CIMECA will be the first event of its kind to be held in the Central America and Caribbean region to include medical and aesthetic professionals, businesses, and the Latin American public. The conference is designed to address the latest advances in aesthetic medicine, cosmetology, and anti-aging procedures from different perspectives.

The convention will feature keynote speeches, panel discussions and presentations on the latest trends, technologies and tools available to promote safe, profitable and ethical medical practices, together with the celebration of the first Aesthetic & Wellness Expo where the general public can participate.

CIMECA will address a wide variety of issues and treatments, including obesity, localized adiposity (the accumulation of fat tissue), cellulite, facial and body aesthetics, skincare. Keynote speeches and panel discussions will be accompanied by clinical case studies, new research in the field of aesthetics, new ideas, products and technologies that offer the latest developments and trends in aesthetic sciences.

CIMECA emerged on the initiative of a group of medical graduates of the Faculty of Medicine at the University of Panama and extension specialists in anti-aging medicine from the John F. Kennedy Argentine University and the Pinto Institute in Buenos Aires.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About CIMECA:

The first IIberoamerican Convention on Antiaging and Aesthetic Medicine Cosmetology (CIMECA), to be held Feb. 17-19 2016, is a unique event that will bring together physicians, medical practitioners, businesses beauty professionals and the public from Panama and throughout Central America. Participants will engage in conferences, keynote speeches, panel discussions and presentations on the latest trends, technologies and tools available to promote safe, profitable and ethical aesthetic medical practices.

Global Stem Cells Group announces the appointment of Kipp Van Camp, D.O., Chief Operating Officer. Van Camp, a former family practitioner and interventional radiologist, was a GSCG advisory board member for years

MIAMI (PRWEB) DECEMBER 08, 2015

Global Stem Cells Group has announced the appointment of Kipp Van Camp, D.O. to the position of Chief Operating Officer for the international biotech company. Van Kamp is an interventional radiologist and former family practitioner with a medical career spanning 25 years.

According to Global Stem Cells Group CEO Benito Novas, Van Camp’ distinct background in medicine, entrepreneurial ventures and corporate management makes him the obvious choice to spearhead a new era of growth for the company.

As COO, Van Camp will take over direct management of GSCG’s day-to-day operations, and make managerial decisions.

Van Camp is the author of “Misdiagnosis: A Practicing Physician’s Case Study of Health Care Reform,” and hosts the popular “Doctor’s Orders” radio show. A native of western Kansas, he is triple board certified in family medicine and radiology, Van Camp co-owns radiology practices in Kansas City and Topeka, Kansas, and is the owner and Medical Director of Rejuvenate Medical Spa in Topeka, where he administers minimally invasive cosmetic treatments.

He serves as an adjunct professor at Washburn University and the University of Kansas. He also engages in clinical and scientific medical research, and serves as the Medical Director of Precise Clinical Research.

For four years, Van Camp served as a member of the Global Stem Cells Group advisory board, and is well acquainted with the company’s mission to bring the latest stem cell therapies to patients worldwide.

“We are very happy to have an esteemed professional like Dr. Van Camp to fill the position of Global Stem Cells Group’s chief operating officer,” Novas says. “He possesses the knowledge, experience, and commitment to the potential of stem cell technology that is necessary to fill this position, which makes him a critical addition to the team, one who will ensure we are well positioned into the future.”

To learn more, visit the Global Stem Cells Group website, Email bnovas@stemcellsgroup.com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Kipp Van Camp, D.O.

An interventional radiologist and former family practitioner, Kipp Van Camp, D.O. (“Dr. Kipp”) is triple board certified in family medicine and radiology. A native of western Kansas, he earned a doctor of osteopathic medicine degree (D.O.) from Kansas City University of Medicine and Biosciences in 1990.

Van Camp is the author of “Misdiagnosis: A Practicing Physician’s Case Study of Health Care Reform,” and hosts the popular“Doctor’s Orders” radio show. He served on the Global Stem Cells Group advisory board for four years.

His formal education includes medical training with two residencies and a fellowship covering a span of nine years of post-graduate education. He began his medical career practicing family medicine in rural northwest Missouri, performing a variety of duties, including delivering babies, pediatrics and elder care. After completing his residency in diagnostic radiology at Oklahoma State University in Tulsa, Van Camp received a fellowship in interventional radiology at Washington Hospital Center in Washington, DC.

His passion for medicine and an entrepreneurial spirit led him to pursue and establish a variety of health-centric ventures. He co-owned radiology practices in Kansas City, Missouri and Topeka, Kansas, and was owner and medical director of Rejuvenate Medical Spa in Topeka, where he administered minimally invasive cosmetic medical treatments.

Van Camp is an adjunct professor at Washburn University and the University of Kansas, and participates in clinical and scientific medical research. He serves as the Medical Director of Precise Clinical Research.

Global Stem Cells Group has announced the opening of two new stem cell centers in the cities of Arica and Iquique in northern Chile. The new centers are the latest part of Global Stem Cells Groups’ expansion efforts in Latin America.

MIAMI (PRWEB) NOVEMBER 30, 2015

Global Stem Cells Group announced the opening of a new core patient care hub with the opening of two new clinics in the cities of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America.

Both the Arica and Iquique clinics offer the most advanced protocols and techniques in stem cell medicine to patients from around the world.

The clinics will be headed by Victor Perez, M.D. and Duval Aguirre, M.D.

Global Stem Cells Group, is expanding its clinical presence throughout Latin America and worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics. The new Arica and Iquique clinics are certified for the medical tourism market.

GSCG is committed to the highest standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

MIAMI, Nov. 24, 2015—GlobalStemCellsGroup has announced plans to participate in the 2t6h annual Argentine Congress of Aesthetic Medicine March 31-April 2, 2016 in Buenos Aires. Physicians and stem cell experts from the U.S. and Argentina will be present to share new findings in regenerative and aesthetic medicine.
Following the symposium, Global Stem Cells Group will conduct an intensive, hands-on course in stem cell harvesting, isolation and re-integration for physicians and qualified medical practitioners who wish to offer stem cell treatments to patients in their office.
Hosted by the pioneering Argentina Society of Aesthetic Medicine (SOARME) in conjunction with the Pinto Institute, the conference will feature acclaimed stem cell aesthetic practitioners from Argentina and the U.S. As a member of the Argentine Medical Association (A.M.A.) and of the International Union of Aesthetic Medicine (U.I.M.E.). SOARME has the scientific support of the John F. Kennedy Argentine University in Buenos Aires, and a host of national and international scientific organizations.
Pinto Institute President Raul Pinto says the symposium will feature the latest therapeutic approaches to aesthetic pathologies, ranging from clinical trials to minimally invasive procedures with low risk to patients.
“This will be the fourth year Global Stem Cells Group participates in the conference, and we’re looking forward to Raul Pinto and the Pinto Institute’s contributions,” says Global Stem Cell Group CEO Benito Novas. “Regenerative aesthetic medicine is one of the fastest growing fields in stem cell applications, and Dr. Pinto and the Pinto Institute has pioneered teaching aesthetic medicine and anti-aging procedures to physicians in Argentina.”
The conference will be held at the Catholic University of Argentina in Buenos Aires.
For more information visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About the Argentina Society of Aesthetic Medicine (SOARME):
Pioneered by Raul Pinto, the Argentina Society of Aesthetic Medicine (SOARME) was accepted into Argentina’s Union Internationale de Medecine Esthetique (UMIE) in 1993, 13 years after Raul Pinto, M.D. became the first physician to bring aesthetic medicine to the Americas. Since then, SOARME has promoted collaboration with aesthetic and plastic surgeons, and worked to improve its safety and efficiency so that aesthetic surgery minimizes the possible risks to patients.
According to SOARME, the objectives of aesthetic medicine include the maintenance, promotion and restoration of aesthetics, beauty and health, for which it uses non-invasive and minimally invasive procedures in clinical practice, and in which topical or local anesthesia is used in an out-patient system. SOARME member countries include France, Italy, Belgium, Spain, Morocco, Uraguay, Argentina, Brazil, Switzerland, Poland, Colombia, Venezuela, Chile, U.S.A., Mexico, Russia, Kazakhstan, Algeria, Canada, Korea, Turkey, South Africa, Ecuador, China, Ukraine and Georgia.
About Raul Pinto, M.D. and the Pinto Institute:
The Pinto Institute, the first school of aesthetic medicine founded in the Americas, began its educational activity in aesthetic medicine and related specialties in 1991 in the Palermo district of Buenos Aires, as the Academic Medical Center Department of the Pinto Institute, and with the support of the Argentina Society of Aesthetic Medicine (SOARME).
In1992, the John F. Kennedy Argentine University provided scientific support and began with the first university training in aesthetic medicine. In 1996, founder Raul Pinto, M.D. issued the first  diploma in aesthetic medicine in the Americas, with international corporate support of the Pan-American Society of Aesthetic Medicine (PASAM) and the Union Internationale de Medecine Esthetique  (UIME) School in Buenos Aires. In 2002, Pinto Institute received the first accreditation in anti-aging medicine, sponsored by the Aesthetic & Anti-Aging Medicine International Society (AAAMISO)  and the European Society of Anti-Aging Medicine (ESAAM).
Pinto Institute offers courses related to aesthetic medicine specialties with accreditation guarantees from the European Applicazioni Società Biomediche (SEAB) and Hispanic American College of Physicians & Surgeons in Miami.
Since 2009, courses have been held in conjunction with the John F. Kennedy Argentine University. In 2010 the school moved to the Puerto Madero neighborhood of Buenos Aires and was renamed Pinto Institute of Teaching and Research in Aesthetic Medicine, freeing up physical space for SOARME to expand development of its scientific activities.
Since 2010, SOARME has directed and  trained students in aesthetic medicine in conjunction with the Medical Association Argentina (AMA) at the Pinto Institute.
###

Global Stem Cells Group announced plans to participate in the Spanish Society of Cosmetic Medicine and Surgery (SEMCC) Mediterannean Conference XXIV of Therapeutic Confrontations in Medicine and Cosmetic Surgery in Sitges, Barcelona, Spain, May 6-8 2016. Members of the GSCG Faculty will represent the biotech company in Barcelona.

MIAMI, NOV. 7, 2015 (PRWEB) DECEMBER 07, 2015

Global Stem Cells Group Faculty members will represent the biotech company at the Spanish Society of Cosmetic Medicine and Surgery (SEMCC) Mediterannean Conference XXIV of Therapeutic Confrontations in Medicine and Cosmetic Surgery in Sitges, Barcelona, Spain, May 6-8 2016.

2016 will mark the third consecutive year Global Stem Cells Group will collaborate with SEMCC President Victor Garcia Gimenez on the conference, designed to advance the aesthetic applications of stem cells. The conference will be followed by an extensive six-hour, hands-on stem cell training class presented by GSCG subsidiary Stem Cell Training, Inc. to provide participating physicians with state-of-the-art techniques for isolating and re-integrating adipose-derived stem cells, along with clinical protocols.

Increasing interest in regenerative medicine among the medical community, along with recent advances in stem cell therapies have motivated Global Stem Cells Group and SEMCC to create programs like this one, designed to promote the most recent studies and supporting investigative protocols for clinical applications. Relevant members of the featured faculties will dictate theory portions of the symposium.

Joining the Global Stem Cells Group Faculty will be: Prof. Angel Raya, M.D., Professor at the Catalan Institute for Research and Advanced Studies (ICREA), Researcher, Home Group Power Control Stem Cell Institute, Bioengineering of Catalonia (IBEC), and Director of the Center for Regenerative Medicine in Barcelona (CMRB); and Prof. Anna Veiga, Biological Sciences Professor at the Pompeu Fabra University and Director of the Stem Cell Bank Center of Regenerative Medicine in Barcelona (CMRB).

Special guests will include: Pier A. Bacci, M.D. (Italy); Maurizio Ceccarelli, M.D. (Italy); Julio Ferreira, M.D. (Argentina); Joan X. Fontdevila, M.D., (Spain); Alfredo Hoyos, M.D. (Colombia); Max Lafontan, M.D. (France); José María Martínez, M.D. (Spain); Maria Jesús Moreno, M.D. (Spain); Kotaro Yoshimura, M.D. (Japan); Patrick Micheels, M.D. (Switzerland); Greg Muller, M.D. (USA); Bruno Bioulac, M.D. (Germany); Jani Van Loghen, M.D. (Netherlands); Elena Rumyantseva (France) and others.

The conference will be held at the Hotel Melia Sitges.

For more information on the SEMCC Conference, visit the Global Stem Cells Group website or the Stem Cell Training, Inc. website, email bnovas(at)stemcellsgroup(dot)com, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for cutting-edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

MIAMI, Nov. 24, 2015—Global Stem Cells Group announced the opening two new stem cell clinics in Tacna and Lima, Peru. The new clinics are part of GSCG’s expansion efforts in Latin America.
Both clinics will be headed by Aldo Parodi, M.D., owner of Clinic La Femme in Tacna, and specialist in regenerative medicine and stem cell therapy. Parodi, a cosmetic surgeon, is a GSCG faculty member.
The Tacna and Lima clinics will focus on offering the most advanced techniques and protocols in cosmetic stem cell medicine to patients from around the world.
Global Stem Cells Group is expanding its clinical presence throughout Latin America and worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics. The new Tacna and Lima clinics are certified for the medical tourism market.
GSCG is committed to providing the highest standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.
For more information, visit the Global Stem Cells Group website, Email bnovas@stemcellsgroup.com, or call 305-560-5337.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
###

Global Stem Cells Group announced new sponsorships for its 2016 symposium series with Copa Airlines and Hilton Worldwide. The sponsorship agreements will help provide GSCG with venue, lodging and transportation for events scheduled to bring the latest in regenerative medicine to medical professionals around the world.
MIAMI, Dec. 8, 2015—Global Stem Cells Group announced new sponsorship agreements with Hilton Hotels and Copa Airlines to offer discounted rates and other perks for event venues, lodging and transportation for the international biotech company’s 2016 stem cell and regenerative medicine symposium series in Latin America.
Copa Airlines, headquartered in Panama City, Panama, operates more than 326 daily scheduled flights to 72 destinations in 30 countries around North, Central and South America, and the Caribbean. Global Stem Cells Group’s sponsorship agreement with the airline provides exclusive travel discounts for GSCG’s Group’s 2016 Latin America Symposium series’ representatives and event participants. It also offers the company opportunities to interact with Copa partner Hilton Worldwide for exclusive discounts when both Copa and Hilton cooperate on specific events.
As the official hotel sponsor for Global Stem Cells, Hilton Worldwide will provide discounted accommodations, services  and amenities to GSCG representatives and symposium participants throughout the symposium series.
The GSCG 2016 symposium series will be a Spanish circuit of disclosure and discussion, of the science related to regenerative medicine. Symposiums will be hosted in Argentina,  Colombia, Chile, Peru, Costa Rica and Ecuador throughout the year.
For more information on GSCG’s 2016 symposiums, visit the Global Stem Cells Group website, email bnovas@stemcellsgroup.com, or call 305-560-5337.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Copa Airlines:
Copa Airlines, a subsidiariy of Copa Holdings, is a leading Latin American provider of passenger and cargo services. The airline currently offesr service to 72 destinations in 30 countries in North, Central and South America and the Caribbean. Throughout Copa Airlines’ more than 65 years of uninterrupted operations, it has transformed the Hub of the Americas in Panama into the leading hub on the continent. Copa operates one of the youngest and most modern fleets in the industry, consisting of 98 aircraft, and has an on-time performance of around 90 percent, on par with major airlines worldwide. Copareceived Skytrax awards for Best Airline and Best Cabin and Airport Crew in Central America and theCaribbeanin 2013.Copa is a member of Star Alliance, the leading global airline network, which currently offers more than 18,500 daily flights to 1321 destinations in 193 countries. To make reservations, select seats, participate in the renowned frequent-flyer program MileagePlus, maintain a trip log, check in for flights, print boarding passes or purchase tickets through secure online transactions in 11 different currencies.
About Hilton Worldwide:
Hilton Worldwide is a leading global hospitality company, spanning the lodging sector from luxury and full-service hotels and resorts to extended-stay suites and focused-service hotels. For 96 years, Hilton Worldwide has been dedicated to continuing its tradition of providing exceptional guest experiences. The company’s portfolio of twelve world-class global brands is comprised of more than 4,440 managed, franchised, owned and leased hotels and timeshare properties, with more than 730,000 rooms in 97 countries and territories, including Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio – A Collection by Hilton, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton HHonors®. Hilton HHonors members who book directly through preferred Hilton channels have access to benefits including free standard Wi-Fi, as well as digital amenities that are available exclusively through the industry-leading Hilton HHonors app, where HHonors members can check-in, choose their room, and access their room using a Digital Key.
###

MIAMI (PRWEB) DECEMBER 08, 2015

Global Stem Cells Group announced plans to develop and host six new symposiums in Argentina, Colombia, Chile, Peru, Costa Rica and Ecuador in 2016. According to Global Stem Cells Group CEO Benito Novas, the lineup of Latin American conferences will be a Spanish circuit of disclosure and discussion of the science related to regenerative medicine.

The decision follows the success of the international biotech company’s four successful symposiums in 2015, focused on regenerative medicine and stem cell therapies, in concert with the steady growth of new stem cell clinics throughout Latin America. GSCG is developing the 2016 symposiums to further educate the medical community and the public on the latest advancements in stem cell therapies.

Hundreds of physicians, researchers and regenerative medicine experts participated in GSCG symposiums held this year in Argentina, Chile, Colombia and Mexico. Thanks to Global Stem Cells Group’s growing network of world-class stem cell researchers, treatment practitioners, and investors committed to advancing stem cell medicine, the company is rapidly moving closer to its goal of making stem cell technologies available to patients throughout Latin America, and training physicians and medical practitioners to bring treatments into their offices.

“We have achieved remarkable success bringing together a variety of committed stem cell advocates, specialists and speakers from the U.S. and around the world to present advancements in stem cell therapies and regenerative medicine to receptive audiences,” Novas says. “In 2016, Global Stem Cells Group plans to further expand the dialogue between the world’s medical and scientific communities in order to advance stem cell technologies and translate them into point of care medicine.

“Our mission of bringing the benefits of stem cell therapies to the physician’s office safely, effectively and in compliance with the highest standards of care in the world is being realized, and we are witnessing the benefits of our efforts to separate myths from facts when it comes to stem cell science and technology.”

In addition to developing its 2016 symposium schedule, Global Stem Cells Group has opened new clinics throughout Latin America, Europe and Asia, expanded its network of strategic alliances with stem cell practitioners and technology developers worldwide, appointed a new chief operating officer, expanded its training course and research divisions, and opened a GMP 1000 facility in Santiago, Chile—all in 2015.

For more information on GSCG’s 2016 symposiums, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group CEO Benito Novas has announced that the company’s Santiago, Chile clinical facility is expected to receive Regenerative Technologies Aliance (RTA) certification in early 2016. RTA certification represents the pinnacle of excellence in stem cell and regenerative medicine.

MIAMI (PRWEB) DECEMBER 08, 2015

Global Stem Cells Group has announced that its clinical facility in Santiago, Chili is expected to receive RTA certification from the Regenerative Technologies Alliance (RTA) Regenetech in early 2016. Earning RTA certification means that GSCG Chile meets the highest standards of excellence in current medical and laboratory practices against established standards.

The RTA certification program is conducted by experts in the field of regenerative and cell-based medicine. The Regenerative Technologies Alliance, a 501(c)3 non-profit organization operated by Regenetech and supported by individuals and institutions committed to bringing peer oversight and transparency to the regenerative and cell-based medicine industry, provides certification for:

• Laboratory Facilities that provide the processing of human tissue for the development of cell-based applications
• Clinical facilities seeking to participate in authorized studies that are approved by Institutional Review Boards (IRB)
• Medical facilities providing cell-based medical therapies to patients.

According to Benito Novas, CEO of Global Stem Cells Group, the GSCG Chile facility will be certified under the direction of David B. Audley, RTA Chair and General Secretary. Audley is a highly regarded medical marketing and management services consultant who co-founded MedTourGlobal after 10 years in the emerging field of regenerative medicine.

Global Stem Cells Group Chile CEO Enrique Testart, M.D. is the founder of Consortia Innovas in Santiago, a medical management company that focuses on helping patients gain access to the latest treatments in regenerative medicine as they become available.

Testart and Novas have collaborated on the push to highlight Chile’s appeal as a destination for patients seeking stem cell therapies for a variety of conditions, and as part of GSCG’s ongoing commitment to expand the reach of stem cell treatments throughout Latin America.

Testart and Novas formed an alliance in September 2014 that placed Testart in charge of all Global Stem Cells Group divisions and programs in Chile, including patient recruiting, physician training and certification trough GSCG subsidiary Stem Cell Training, and stem cell equipment and disposables sales through GSCG subsidiary Adimarket. Being scheduled for RTA certification, Novas says, is largely due to Testart’s knowledge and dedication to helping patients gain access to the latest regenerative medicine treatments available today.

“Dr. Testart is a committed colleague and a great asset to Global Stem Cells Group,” Novas says. “His dedication and hard work over the past 14 months is a large part of he Chile facility’s achievements.”

Novas says that GSCG aims to have all the company’s clinical facilities earn RTA certification by the end of 2016.

Global Stem Cells Group in Chile represents one of the largest integrated science and technology organizations associated with tissue engineering and tissue regeneration. GSCG represents the areas of research, development, medical appliances, equipment and protocols for clinical standards. GSCG is fast becoming a global leader in adult stem cell therapies, medical training in stem cell protocols, and the manufacture of high quality products and supplies in regenerative medicine.

Their strategic leadership puts them in the forefront of stem cell research, medical education and patient care. Global Stem Cells Group comprises six companies, each of which works in specialty areas related to the stem cell industry .

To learn more, visit the Global Stem Cells Group website, Email bnovas@stemcellsgroup.com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.